In Brief: Gull Laboratories
This article was originally published in The Gray Sheet
Executive Summary
Gull Laboratories: Receives 510(k) clearance for its semi-quantitative Mumps IgG Elisa test as an aid in the diagnosis of infection caused by the mumps virus, the Salt Lake City-based firm says. Users of the test, which provides results in approximately 90 minutes, have the option to run either one 8-well strip at a time or the full 96-well microtiter plate. Data shows that the test has a relative sensitivity of 97.5% and a relative specificity of 100%...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.